法国肥胖危重症患者拔管后无创通气的效果:一项多中心、非盲、实用性随机临床试验
在法国39个ICU进行的多中心、平行组、实用性随机对照试验,纳入981例肥胖危重症拔管患者,1:1随机分配至无创通气组(交替使用经鼻高流量氧疗或标准氧疗)或氧疗组(经鼻高流量氧疗或标准氧疗)。主要终点为拔管后3天内治疗失败(再插管、更换研究治疗或提前终止研究治疗的复合终点),无创通气组13.5%(66/490)vs 氧疗组26.5%(130/491),相对风险0.43(95%CI 0.31-0.60,p<0.0001)。3天内再插管率在意向性分析中无显著差异(10% vs 12%,p=0.26),但在事后交叉分析中无创通气组更低(9% vs 13%,p=0.037)。无严重不良事件报告。
要点
- 肥胖危重症患者拔管后使用无创通气(交替经鼻高流量氧疗或标准氧疗)较氧疗降低3天内治疗失败率:13.5%(66/490)vs 26.5%(130/491),RR 0.43(95%CI 0.31-0.60,p<0.0001)。
- 内科或外科状态未改变无创通气对治疗失败率的影响。
- 拔管后3天内再插管率在意向性分析中无显著差异:无创通气组10%(48/490)vs 氧疗组12%(59/491),p=0.26。
- 事后交叉分析中再插管率无创通气组更低:9%(51/560)vs 13%(56/421),p=0.037。
- 未报告严重不良事件。
适用人群与场景
- 法国39个ICU中接受拔管的肥胖危重症成人患者。
处置流程与药物剂量
- 无创通气组:拔管后使用无创通气,交替使用经鼻高流量氧疗或标准氧疗。
- 氧疗组:拔管后使用经鼻高流量氧疗或标准氧疗。
研究设计与关键结果
- 研究类型:多中心、平行组、实用性随机对照试验,39个ICU,纳入981例(筛选1650例),1:1随机分配至无创通气组或氧疗组,嵌套1:1随机分配至经鼻高流量氧疗或标准氧疗。
- 主要终点:拔管后3天内治疗失败(再插管、更换研究治疗或提前终止研究治疗的复合终点),无创通气组13.5%(66/490)vs 氧疗组26.5%(130/491),RR 0.43(95%CI 0.31-0.60,p<0.0001)。
- 内科或外科状态未改变无创通气对治疗失败率的影响。
- 3天内再插管率意向性分析:无创通气组10%(48/490)vs 氧疗组12%(59/491),p=0.26。
- 3天内再插管率事后交叉分析:无创通气组9%(51/560)vs 氧疗组13%(56/421),p=0.037。
- 未报告严重不良事件。
证据类型、等级与局限
- 证据类型:多中心、非盲、实用性随机对照试验;统计学家对分组设盲。
- 局限:主要终点的差异大多归因于氧疗组患者转换为无创通气,需要更多证据才能得出无创通气策略可改善以患者为中心的结局的结论。
对床旁实践的改变
- 作者认为:结果与临床实践相关,支持在肥胖危重症患者拔管后使用无创通气。
指南或共识出处
- Lancet Respir Med
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Non-invasive ventilation (NIV) and oxygen therapy (high-flow nasal oxygen [HFNO] or standard oxygen) following extubation have never been compared in critically ill patients with obesity. We aimed to compare NIV (alternating with HFNO or standard oxygen) and oxygen therapy (HFNO or standard oxygen) following extubation of critically ill patients with obesity.
METHODS: In this multicentre, parallel group, pragmatic randomised controlled trial, conducted in 39 intensive care units in France, critically ill patients with obesity undergoing extubation were randomly assigned (1:1) to either the NIV group or the oxygen therapy group. Two randomisations were performed: first, randomisation to either NIV or oxygen therapy, and second, randomisation to either HFNO or standard oxygen (also 1:1), which was nested within the first randomisation. Blinding of the randomisation was not possible, but the statistician was masked to group assignment. The primary outcome was treatment failure within 3 days after extubation, a composite of reintubation for mechanical ventilation, switch to the other study treatment, or premature discontinuation of study treatment. The primary outcome was analysed by intention to treat. Effect of medical and surgical status was assessed. The reintubation within 3 days was analysed by intention to treat and after a post-hoc crossover analysis. This study is registered with ClinicalTrials.gov, number NCT04014920.
FINDINGS: From Oct 2, 2019, to July 17, 2021, of the 1650 screened patients, 981 were enrolled. Treatment failure occurred in 66 (13·5%) of 490 patients in the NIV group and in 130 (26·5%) of 491 patients in the oxygen-therapy group (relative risk 0·43; 95% CI 0·31-0·60, p<0·0001). Medical or surgical status did not modify the effect of NIV group on the treatment-failure rate. Reintubation within 3 days after extubation was similar in the non-invasive ventilation group and in the oxygen therapy group in the intention-to-treat analysis (48 (10%) of 490 patients and 59 (12%) of 491 patients, p=0·26) and lower in the NIV group than in the oxygen-therapy group in the post-hoc cross-over (51 (9%) of 560 patients and 56 (13%) of 421 patients, p=0·037) analysis. No severe adverse events were reported.
INTERPRETATION: Among critically ill adults with obesity undergoing extubation, the use of NIV was effective to reduce treatment-failure within 3 days. Our results are relevant to clinical practice, supporting the use of NIV after extubation of critically ill patients with obesity. However, most of the difference in the primary outcome was due to patients in the oxygen therapy group switching to NIV, and more evidence is needed to conclude that an NIV strategy leads to improved patient-centred outcomes.
FUNDING: French Ministry of Health.
参考来源
- De Jong A, Bignon A, Stephan F, et al. Effect of non-invasive ventilation after extubation in critically ill patients with obesity in France: a multicentre, unblinded, pragmatic randomised clinical trial. Lancet Respir Med. 2023. PMID: 36693403. doi:10.1016/S2213-2600(22)00529-X
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。